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Treatment Response in Depressed Adolescents
With and Without Co-Morbid Attention-Deficit=Hyperactivity
Disorder in the Treatment for Adolescents
with Depression Study
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Vishal Madaan, M.D.,1 Susan E. Puumala, M.S.,1 John F. Curry, Ph.D.,2 John Walkup, M.D.,3
Hayden Kepley, Ph.D.,4 Benedetto Vitiello, M.D.,5 and John S. March, M.D.2

Abstract

Objective: In the Treatment for Adolescents with Depression Study (TADS), fluoxetine (FLX) and the combination of
fluoxetine with cognitive-behavioral therapy (COMB) had superior improvement trajectories compared to pill placebo
(PBO), whereas cognitive–behavioral therapy (CBT) was not significantly different from PBO. Because attention-deficit=
hyperactivity disorder (ADHD) and major depressive disorder (MDD) frequently co-exist, we examined whether ADHD
moderated these outcomes in TADS.
Method: A total of 439 adolescents with MDD, 12–17 years old, were randomized to FLX, CBT, COMB, or PBO. Random
coefficients regression models examined depression improvement in 377 depressed youths without ADHD and 62 with
ADHD, including 20 who were treated with a psychostimulant.
Results: Within the ADHD group, the improvement trajectories of the three active treatments were similar, all with rates
of improvement greater than PBO. For those without ADHD, only COMB had a rate of improvement that was superior to
PBO.
Conclusions: Co-morbid ADHD moderated treatment of MDD. CBT alone or FLX alone may offer benefits similar to COMB
in the treatment of MDD in youths with co-morbid MDD and ADHD, whereas monotherapy may not match the benefits of
COMB for those without ADHD. The ADHD subgroup analysis presented in this paper is exploratory in nature because of the
small number of youths with ADHD in the sample.
Clinical Trial Registry: www.clinicaltrials.gov Identifier: NCT00006286. The TADS protocol and all of the TADS manuals
are available on the Internet at https:==trialweb.dcri.duke.edu=tads=index.html.

Introduction

A

ttention-deficit=hyperactivity disorder (ADHD) and
depressive disorders are common in the pediatric population,
with as many as 20–30% of children and adolescents diagnosed
with ADHD concurrently experiencing a depressive disorder

(Anderson et al. 1987; Biederman et al. 1991; American Psychiatric
Association 1994; Angold et al. 1999). Studies by Biederman et al.
have demonstrated that adolescents with ADHD have a 2.5 times
higher risk for major depressive disorder (MDD) than those
without ADHD (Biederman et al. 2008). Because each disorder
independently can lead to significant functional impairment, the
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frequency and impact of simultaneously experiencing the combination of MDD and ADHD is clearly of great clinical concern.
To date, there is a lack of strong evidence supporting a single
treatment for co-morbid MDD and ADHD in adolescents. Of the
available pharmacological treatments, tricyclic norepinephrine reuptake inhibitors (e.g., desipramine, nortriptyline) have been
shown to improve symptoms of ADHD in pediatric populations and
depression in adults. The use of these inhibitors in adolescents has
been limited by safety and tolerability concerns, and their efficacy
as antidepressants has not been well established in this population
(Biederman et al. 1993; Wilens et al. 1993; Geller et al. 1999;
Prince et al. 2000). Selective serotonin reuptake inhibitors (SSRIs)
have demonstrated benefits in adolescent depression and are associated with fewer adverse effects and reduced overdose toxicity,
as compared to tricyclic antidepressants, but there is little evidence
of efficacy in ADHD (Barrickman 1991; Goldstein and Goodnick
1998; Quintana et al. 2007). Studies have also examined the use of
atomoxetine in co-morbid youths. An open-label study of children
and adolescents found that atomoxetine, alone or in combination
with fluoxetine, improved symptoms of ADHD and depressive
symptoms (Kratochvil et al. 2005). However, in a later doubleblind, placebo-controlled study, atomoxetine improved ADHD
symptoms, but did not significantly differ from placebo in improving depressive symptoms (Atomoxetine ADHD and Comorbid
MDD Study Group et al. 2007). In an open-label trial of bupropion
sustained-release, 14 of 24 adolescents were rated as responders in both depression and ADHD, providing data supportive of
further placebo-controlled studies of bupropion (Daviss et al.
2001).
Combination pharmacological treatments, such as use of an
SSRI along with a stimulant have not been well studied, other than
an open-label study using a sample of adults and adolescents with
ADHD. This study demonstrated that further global improvements
were achieved in attention, behavior, and affect when methylphenidate (MPH) was added to either fluoxetine or sertraline (Findling
1996; Stoll et al. 1996). To date, no large randomized trials have
investigated combinational pharmacological treatments of comorbid ADHD and MDD.
Nonpharmacological treatments, such as cognitive–behavioral
therapy (CBT) and interpersonal therapy (IPT), have been shown to
be moderately effective in the treatment of depressed adolescents
(Birmaher et al. 1996; Reinecke et al. 1998; Lewinsohn et al. 1999;
Mufson and Sills 2006). Although several studies have suggested
that CBT may be helpful in decreasing functional impairment in
depressed adolescents, large controlled studies of CBT that are
specific to adolescents with co-morbid ADHD and MDD have not
been conducted (Antshel and Barkley 2008).
The Treatment for Adolescents with Depression Study (TADS)
was a clinical trial of 439 depressed adolescents that compared the
effectiveness of four randomized treatments: Pharmacotherapy
with fluoxetine (FLX), CBT, the combination of FLX plus CBT
(COMB), and clinical management with pill placebo (PBO). Because half of the adolescents in TADS met criteria for at least one
co-morbid psychiatric disorder at baseline, the study provided an
opportunity to examine the impact that having a co-morbid diagnosis of ADHD had on the outcome of treatment in depressed
adolescents who participated in TADS. Given the high level of
impairment that may result from ADHD alone, we hypothesized
that TADS participants with co-morbid ADHD would be less likely
to respond or would respond differentially to TADS treatment
across: (1) The 12-week blinded portion of the study, and (2) the
entire 36-week treatment period. Our secondary hypotheses are
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based on past literature of samples of youths with co-morbid
ADHD and MDD. We expected that, at baseline, TADS participants with ADHD would have a greater severity of MDD symptoms, a higher level of global impairment, and increased suicidality
in comparison to participants without ADHD. Additionally, we
expected that TADS participants with ADHD, as compared to those
without ADHD, would be more likely to prematurely terminate
treatment and drop out of the study.
Methods
TADS sample and design
The rationale, design, methods, and sample characteristics of
TADS (TADS 2003; TADS 2005), along with the 12-week acute
treatment (TADS 2004) and the overall 36-week treatment outcomes (TADS 2007), have been described in great detail in prior
publications. Only those aspects of the study that are directly relevant to these analyses will be presented. In summary, TADS was a
publicly funded, randomized controlled trial (RCT) conducted
between 2000 and 2003 to evaluate the 12-week and 36-week
outcomes of four treatments for MDD: FLX (n ¼ 109), CBT
(n ¼ 111), COMB (n ¼ 107), and PBO (n ¼ 112). PBO was included
as a control only during the first 12 weeks of treatment. TADS
enrolled 439 adolescents, ages 12–17 years, including 54.4% females and 74.8% Caucasians. Adolescents were excluded if they
were considered to be at especially high risk for suicide, as evidenced by a recent history of suicidal behavior or prominent suicidal ideation, or if they had co-morbid substance abuse, bipolar
disorder, severe conduct disorder, thought disorder, or were deemed
at ‘‘high-risk’’ for self-injurious or aggressive acts (TADS 2003).
After 12 weeks of acute treatment, the two blinded pharmacotherapy treatments (PBO, FLX) were unblinded and PBO treatment
was discontinued regardless of response. Youths who were randomized to an active treatment (FLX, CBT, COMB) and had at
least partial improvement in symptom severity continued their
randomized treatment for 24 additional weeks.
TADS was somewhat unique among pediatric MDD trials in that
participants were allowed to continue concomitant treatment with a
psychostimulant for ADHD, as long as other eligibility criteria for
TADS were met, and the psychostimulant’s dose had been stable
(25% change in dose) during the preceding 6 months. The community-prescribing clinician ceded control of the psychostimulant
treatment to the TADS pharmacotherapist if the adolescent was
assigned to a pharmacological treatment condition, whereas the
community clinician continued treatment management if assigned
to CBT alone (TADS 2003). The TADS protocol and procedures
were approved by each site’s local Institutional Review Board, and
a National Institute of Mental Health (NIMH) Data and Safety
Monitoring Board monitored the study. Written parental consent
and written participant assent were obtained for all subjects (TADS
2003; TADS 2005).
The diagnoses of MDD and co-morbid conditions for current and
past episodes were established prior to randomization using the
Schedule for Affective Disorders and Schizophrenia for SchoolAge Children–Present and Lifetime Version (K-SADS-PL)
(Kaufman et al. 1997). Of the 439 enrolled participants in TADS,
60 met current Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (American Psychiatric Association
1994) criteria for ADHD, of any subtype. Two additional participants were included in our sample that had a history of ADHD and
were currently taking a psychostimulant for ADHD, but did not
have a current diagnosis of ADHD. For the purpose of this manu-
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script, 62 (14.1%) TADS participants were identified as having
ADHD, including 20 participants (32.3% of the ADHD sample)
who had been taking a stable dose of a psychostimulant for ADHD
at study entry.
Primary outcome measure
The primary outcome measure for our analyses was the Children’s Depression Rating Scale–Revised (CDRS-R) clinicianbased total scores at baseline evaluation and as reassessed each 6
weeks until the end of acute treatment at week 12 and end of the
study treatment at week 36. The CDRS-R is a 17-item measure of
depression severity over the past week that was administered by an
independent evaluator, an experienced clinician who was masked
as to the adolescent’s assigned treatment. Separate adolescent and
parent interviews were completed to yield a clinician summary
score, ranging from 17 to 113, with higher scores representing more
severe depression. The scale has good internal consistency (coefficient alpha ¼ 0.85), interrater reliability (r ¼ 0.92), test–retest
reliability (r ¼ 0.78), and is correlated with a range of validity indicators, including global ratings and a diagnosis of depression
(Poznanski and Mokros 1995). A score of 45 or greater (indicating
at least moderate clinical depression) was required for TADS study
entry. At TADS baseline, the CDRS-R total scores ranged from 45
to 98 (mean 60, standard deviation [SD] ¼ 10.4), which translates
to a normed T-score of 75.5 (SD ¼ 6.43), indicating moderate to
moderately severe depression (TADS 2005).
Baseline indicators
Several clinical indicators were used in these analyses to examine differences among the subgroups’ characteristics at study
entry. Psychometric properties and intercorrelations for these
measures are acceptable and have been reported in prior publications (TADS 2003; TADS 2005). The Reynolds Adolescent Depression Scale (RADS) (Reynolds 1987a) is a 30-item adolescent
report of depression severity over the past month, with a total score
ranging from 30 to 150. In TADS, more than half (58.9%) of participants had a total score of 77 at baseline, indicating moderately
severe clinical depression, whereas 19.6% had a total score indicating severe to extreme clinical depression (TADS 2005). Suicidal
ideation over the past month was measured by a 15-item subscale of
the Suicidal Ideation Questionnaire–Junior High School Version
(SIQ-Jr) (Reynolds 1987b). A cutoff score of 31 generally indicates suicidal ideation of sufficient severity to warrant prompt
clinical evaluation and is used in this analysis. At baseline, 30.3%
of participants met this flag criterion on the SIQ-Jr. The 100-point
Children’s Global Assessment Scale (CGAS) (Shaffer et al. 1983)
is a clinician rating of general functioning over the past week, with
higher scores indicating better functioning.
The Conners’ Parent Rating Scale–Revised: Long Version
(CPRS-R:L) (Conners 1997) is an 80-item parent rating of ADHD
symptoms and other problem behaviors. Total subscale scores are
converted into normed T-scores, with 66–70 considered moderately atypical, and >70 considered atypical. CPRS-R:L subscale Tscores used in this analysis include: Oppositional, hyperactivity,
cognitive problems, ADHD index, global index, and DSM-IV total
symptoms, which is further divided into DSM-IV Inattentive
symptoms and DSM-IV Hyperactivity=Impulsivity symptoms. The
ADHD index is a set of items found useful for identifying ‘‘at-risk’’
youth for ADHD, whereas the Conners global index represents overall psychopathology, loading on two factors: Restless=
impulsivity and emotional lability (Conners 1997).
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Premature termination and study dropout
TADS (2003) defined premature termination as having discontinued assigned study treatment to begin an out-of-protocol
treatment, while continuing to participate in study assessments
conducted every 6 weeks. The decision to terminate treatment
prematurely was based solely upon the clinician’s recommendation
and not due to mere lack of response or treatment preference. A
study dropout was defined as having withdrawn consent or having
discontinued assigned treatment and study assessments.
Statistical analyses
Descriptive statistics were used to summarize sample characteristics. Frequencies and percentages summarized categorical
data, whereas means (SD) summarized continuous data. All analyses were conducted using SAS 8.2 (SAS Institute 2002). Due to
the exploratory nature of the analysis, statistical significance was
set at p ¼ 0.05 for each nondirectional test. The two ADHD subgroups (MDD with and without ADHD) were compared on key
demographic and clinical indicators prior to initiation of treatment.
Fisher exact tests were employed for binary measures because
some comparisons had small cell sizes, and Student t-tests were
used for continuous measures. Chi-squared tests were used to test
for differences in the proportion of youths randomized to each
treatment condition within the two ADHD subgroups.
By definition, a moderator of treatment outcome is a pretreatment variable that is not correlated with treatment, but interacts
with treatment resulting in a different profile of treatment effects
within the moderator subgroups. A nonspecific predictor of outcome, on the other hand, is a pretreatment variable that is not
associated with treatment but significantly influences outcome regardless of treatment condition.
We conducted two intent-to-treat (ITT) analyses on the CDRS-R
total scores collected across assessments to determine whether the
ADHD diagnosis was a nonspecific predictor or moderator of
treatment outcome across 12 weeks of acute treatment and 36
weeks. This analysis was conducted using the methodological approach recommended by Kraemer and colleagues (2002), and was
the same analytic approach applied in the primary efficacy analysis
of TADS (TADS 2004; TADS 2007), with the exception that the
overall analyses incorporated the ADHD subgroup and its interactions tested whether ADHD influenced outcome over 12 weeks
and=or 36 weeks.
Longitudinal analyses of the CDRS-R total score were conducted with random coefficients regression models (RRM) (Brown
and Prescott 1999) to compare the short-term outcome of four
treatments during the initial 12-week acute treatment period and the
long-term outcome across 36 weeks of the three active treatments
(e.g., COMB, FLX, and CBT). The PBO treatment arm was omitted
in the longer-term week-36 analysis due to the discontinuation of
PBO after 12 weeks. The ITT analyses included all enrolled participants in the treatment groups to which they were randomly
assigned, regardless of their protocol adherence, actual treatment
received, and=or subsequent withdrawal or deviation from the
protocol. The overall RRM model for the week-12 and week-36
analyses included the: (1) Fixed effects of site, treatment, time,
treatment-by-time, ADHD subgroup, and its two- and three-way
interactions, and (2) random effects of participant and participantby-time on the CDRS-R total score. Site was retained in the model
as a covariate because treatments were nested within site and time
was defined as the natural log of time þ 1 (measured as days since
randomization). Although the temporal effects were significantly

522

KRATOCHVIL ET AL.

linear over the initial 12 weeks, the relationship was quadratic
(nonlinear) over the 36 weeks. Thus, the final analysis model for the
initial 12 weeks was a hierarchical linear mixed model, whereas the
week-36 data was analyzed using a hierarchical quadratic mixed
model.
For the 439 depressed adolescents included in the week-12
analysis, the two subgroups included youths diagnosed with ADHD
(n ¼ 62) and without ADHD (n ¼ 377). Because the PBO arm was
omitted from the week-36 analysis, the sample of 327 included a
smaller number of youths with ADHD (n ¼ 43) and without ADHD
(n ¼ 284). If the above omnibus model indicated a significant
ADHD-by-treatment or ADHD-by-treatment-by-time interaction,
then a separate RRM for each ADHD subgroup was conducted to
examine the fixed effects of site, treatment, treatment-by-time, as
well the random effects of participant and participant-by-time. For
each conducted RRM that resulted in a significant treatment or
treatment-by-time effect ( p  0.05), a posteriori paired contrasts
were conducted to examine treatment differences.
For the 62 youths in the ADHD subgroup, we also conducted a
24 analysis of variance using a general linear model approach to
examine the effects of stimulant medication use and treatment assignment and interaction on CDRS-R total scores at baseline. For
this analysis, we included the subgroup of depressed adolescents
with ADHD who, at baseline, were currently treated with a stimulant medication (n ¼ 20) and those untreated for ADHD (n ¼ 42).
Results
Of the 439 enrolled adolescent participants in TADS, 62 (14.1%)
were assessed as having a diagnosis of ADHD at study entry. TADS
participants with ADHD had a mean age of 14.6 (SD 1.5) years at
time of consent. There were twice as many males (66.1%) as females ( p < 0.004) in our sample of depressed adolescents who had
a diagnosis of co-morbid ADHD. No difference was found in assigned treatment among participants who did or did not have a
diagnosis of ADHD (w2 ¼ 1.10, p ¼ 0.777). Among the 62 youths
with ADHD, 14 (22.6%) were assigned to CBT, 14 (22.6%) assigned to FLX, 15 (24.2%) to COMB, and 19 (30.6%) to PBO.
Table 1 presents baseline demographic and clinical indicators for

the subgroups of TADS participants who did or did not have a comorbid diagnosis of ADHD at study entry and who were included
in the week-12 analysis.
Mean (SD) for T-scores on the CPRS-R:L subscales, measuring
parent-reported ADHD symptoms and other problem behaviors, are
presented in Table 2.
Premature termination and study dropout
There was no statistical difference ( p ¼ 0.999) among participants with or without a diagnosis of ADHD who prematurely terminated their assigned treatment by week 12, after a TADS
clinician recommended an out-of-protocol treatment, including 6
(9.7%) with ADHD and 36 (9.6%) without ADHD. Furthermore,
there was no significant difference found in the rate of study
dropout at end of the 12-week acute treatment ( p ¼ 0.378), including 9 (14.5%) with ADHD and 39 (10.3%) without ADHD.
Additionally, there was no significant difference ( p ¼ 0.755) found
in the rate of dropout for the overall 36-week treatment among
participants with or without a diagnosis of ADHD, including 17
(27.4%) youths with ADHD and 96 (25.5%) without ADHD who
dropped out of TADS.
12-Week blinded treatment outcome ( N ¼ 439)
The overall linear RRM completed for the 439 enrolled participants over the 12-week acute blinded-treatment period indicated a
significant site effect (F(12, 422) ¼ 1.78; p ¼ 0.050), linear time effect (F(1,422) ¼ 457.92; p < 0.001), treatment-by-time interaction
(F(3,421) ¼ 3.38; p ¼ 0.018), and ADHD-by-treatment-by-time interaction (F(3,421 ¼ 3.11; p ¼ 0.026), with the remaining fixed effects nonsignificant ( p > 0.050). The significant ADHD interaction
demonstrated that improvement in depression was moderated by
ADHD status prior to treatment or having a diagnosis of ADHD
prior to study entry. A separate RRM was then completed for each
ADHD subgroup and showed that each subgroup had a significant
time (without ADHD: F(5,355) ¼ 945.58; p  0.001; with ADHD:
F(1,53) ¼ 145.18; p < 0.001) and treatment-by-time interaction
(without ADHD: F(3,355) ¼ 9.55; p < 0.001; ADHD: F(3,53) ¼ 3.03;
p ¼ 0.038) effects.

Table 1. Baseline Indicators of Depressed Adolescents with and without ADHD
TADS youth with ADHD n ¼ 62
Gender (male)
Caucasian
Initial depressive episode
Depression severity (CDRS-R total)
Adolescent-reported MDD (RADS total)
Global functioning (CGAS rating)
Potential risk of suicidality flag (SIQ-Jr)
Current dysthymia disorder
Current anxiety disorder
Current oppositional defiant disorder
Current substance abuse disorder
Current alcohol abuse disorder

n (%)
n (%)
n (%)
Mean (SD)
Mean (SD)
Mean (SD)
n (%)
n (%)
n (%)
n (%)
n (%)
n (%)

41
50
50
57.58
74.46
50.05
14
11
12
18
1
1

(66.13%)
(80.65%)
(81.97%)
(9.87)
(12.61)
(7.70)
(23.73%)
(17.74%)
(19.35%)
(29.03%)
(1.61%)
(1.61%)

Without ADHD n ¼ 377
159
274
319
60.52
80.01
49.57
111
35
108
40
6
2

(42.18%)
(72.68%)
(86.68%)
(10.43)
(14.48)
(07.44)
(30.08%)
(9.31%)
(28.72%)
(10.61%)
(1.59%)
(0.53%)

p value
<0.005
0.214
0.322
0.030
0.003
0.690
0.358
0.070
0.166
<0.001
1.000
0.358

Table’s values are expressed as n ¼ number of randomized participants (percentage [%]), or as a group mean (standard deviation [SD]). For mean data,
p values represent the Fisher exact tests for binary measures and Student t-tests for continuous measures.
Anxiety disorder includes the diagnoses of panic disorder, separation anxiety disorder, specific phobia, social phobia, agoraphobia, generalized anxiety
disorder, posttraumatic stress disorder, and=or acute stress disorder.
Abbreviations: ADHD ¼ Attention-deficit=hyperactivity disorder; TADS ¼ Treatment for Adolescents with Depression Study; CDRS-R ¼ Children’s
Depression Rating Scale–Revised; MDD ¼ major depressive disorder; RADS ¼ Reynolds Adolescent Depression Scale; SIQ-Jr ¼ Suicidal Inventory
Questionnaire–Junior High School Version.
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Table 2. Conners’ Parent Rating Scale–Revised Subscale T-Scores
Youth With ADHD n ¼ 62
Oppositional subscale
Cognitive problems subscale
Hyperactivity subscale
ADHD index
Conners’ Global Index
DSM-IV Total Symptoms
DSM-IV Inattention Symptoms
DSM-IV Hyperactivity=Impulsivity

74.62
76.35
77.41
78.57
80.23
80.54
78.40
77.06

(10.89)
(09.25)
(15.56)
(08.71)
(11.38)
(9.99)
(08.88)
(15.62)

Without ADHD n ¼ 377
70.05
67.57
62.55
67.81
71.01
67.33
68.20
60.89

(13.25)
(11.95)
(14.91)
(11.68)
(13.03)
(12.37)
(12.25)
(13.35)

t-Value

p Value

ÿ2.87
ÿ4.51
ÿ5.44
ÿ7.25
ÿ4.51
ÿ7.88
ÿ6.73
ÿ6.01

0.005
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

Conners’ Parent Rating Scale, Revised-Long Version subscale values are expressed as T-score group means and standard deviation (SD) at baseline.
p values are for Student t-tests. ADHD Index subscale consists of items useful for identifying ‘‘at risk’’ youth for ADHD. Global Index measures
psychopathology of two factors: Restless=impulsivity and emotional lability. DSM-IV Total Symptoms subscale items match to diagnostic criteria of
combined subtype of ADHD, while DSM-IV Inattention Symptoms subscale matches to inattentive subtype of ADHD, and DSM-IV
Hyperactivity=Impulsivity subscale matches to ADHD subtype.
Abbreviations: ADHD ¼ Attention-deficit=hyperactivity disorder; DSM-IV ¼ Diagnostic and Statistical Manual of Mental Disorders, 4th edition.

For the 377 depressed youths in TADS without ADHD, the
profile for the rate of improvement across 12 weeks was: COMB >
(FLX > CBT) ¼ PBO. The COMB treatment condition had a significantly faster average trajectory of change across 12 weeks
( p < 0.009) relative to FLX, CBT, or PBO. Neither FLX
( p ¼ 0.425) nor CBT ( p ¼ 0.065) was significantly different than
PBO in terms of rate of improvement, although FLX ( p ¼ 0.008)
had a significantly greater average improvement rate compared to
CBT, indicating that CBT had the most gradual improvement trajectory among the active treatments.
A different pattern of treatment effects was observed for the 62
depressed youths with ADHD, which was (CBT ¼ FLX ¼ COMB)
> PBO. Compared to PBO, the treatment conditions of CBT
( p ¼ 0.013), FLX ( p ¼ 0.024), and COMB ( p ¼ 0.046) showed
significantly greater average rates of improvement during the 12week blinded treatment. None of the three active treatments was
significantly different in terms of their change trajectories (all
p > 0.050).
Improvement, as measured by lower mean CDRS-R scores, was
observed in all four treatment conditions of both subgroups over the
12-week blinded-treatment period, which included three assessment visits at baseline and at weeks 6 and 12. The mean CDRS-R
scores over the 12-week period, adjusted for the fixed and random
effects in the analytic model, are presented in Table 3 for the two
ADHD subgroups, and presented graphically in Fig. 1.
The CGI-I response rate at week 12, using last observation
carried forward (LOCF) when a score was missing, was 53.3% for
the youths without ADHD and 45.2% for those with ADHD

(chi ¼ 1.4, degrees of freedom [df] ¼ 1, p ¼ 0.230, effect size ¼
0.2). Table 4 presents the between-treatment effect sizes at week 12
for the two subgroups of depressed adolescents, with and without
ADHD.
36-week treatment outcome (N ¼ 327)
The analysis, which included an adjustment for a significant
quadratic temporal relationship (time2) of the three active treatment
conditions and the CDRS-R total scores across 36 weeks, also
demonstrated a moderator effect for ADHD status. The overall
analysis demonstrated a significant time (F(1,1456) ¼ 45.59; p <
0.001), ADHD-by-time2 (quadratic) interaction (F(1,1298 ¼ 5.04;
p ¼ 0.025), ADHD-by-treatment-by time interaction (F(2,145) ¼
5.60; p ¼ 0.004), and ADHD-by-treatment-by-time2 interaction
(F(2,1297 ¼ 5.53; p ¼ 0.004), while the remaining fixed effects were
nonsignificant (all p < 0.050). The significant ADHD-by-treatment-by-time2 interaction demonstrated that having a diagnosis of
ADHD had a moderating effect during the 36-week treatment
period.
For the 284 youths without ADHD, there was a significant
treatment-by-time2 interaction (F(2,1127) ¼ 23.56; p < 0.001) in
which there was a significant difference in the improvement trajectory of this subgroup. As during the initial 12 weeks, the most rapid
rate of improvement was observed in the COMB condition (all
p > 0.050), which was significantly different from CBT and FLX in
terms of trajectories, with CBT having a significantly more gradual
improvement over the 36 weeks relative to COMB and FLX. Paired

Table 3. Mean Adjusted CDRS-R Total Scores for the 12-Week Analysis (N ¼ 439)
Fluoxetine alone
Youth with
ADHD
n ¼ 14

Without
ADHD
n ¼ 95

CBT alone
Youth with
ADHD
n ¼ 14

Without
ADHD
n ¼ 97

Baseline 56.08  3.93 59.36  4.24 60.01  4.66 59.59  4.78
Week 6 37.05  6.03 40.37  7.33 39.45  5.68 44.98  8.22
Week 12 33.29  6.42 36.83  8.11 35.95  6.34 42.35  8.96

Combination (CBT þ fluoxetine)
Youth with
ADHD
n ¼ 15

Without
ADHD
n ¼ 92

58.59  7.33
40.73  8.54
37.08  9.42

61.14  4.78
37.58  7.67
33.30  8.14

Pill placebo
Youth with
ADHD
n ¼ 19

Without
ADHD
n ¼ 93

55.55  4.50 62.33  4.43
45.25  5.30 44.59  7.42
43.31  5.65 41.39  8.07

Mean adjusted scores derived from the subgroup analyses.
Abbreviations: CDRS-R ¼ Children’s Depression Rating Scale–Revised; ADHD ¼ attention-deficit=hyperactivity disorder; CBT ¼ cognitive–behavioral
therapy.
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Table 4. Between-Treatment Effect Sizes at Week 12
for Adolescents, with and without ADHD
Treatment comparison
Active treatment versus PBO
COMB versus PBO
FLX versus PBO
CBT versus PBO

Youths
without ADHD

Youths
with ADHD

1.0
0.6
ÿ0.1

0.8
1.7
1.2

Abbreviations: ADHD ¼ Attention-deficit=hyperactivity disorder; PBO ¼
pill placebo; COMB ¼ combinational treatment with cognitive–behavioral
therapy plus fluoxetine; FLX ¼ fluoxetine; CBT ¼ cognitive–behavioral
therapy.

as compared to the group of 43 youths who were not treated for
ADHD (F(1,54) ¼ 0.34, p ¼ 0.056). Additionally, no significant
treatment-by-psychostimulant use interaction was found
( p > 0.050).
Discussion
This analysis examines the impact of having a co-morbid diagnosis of ADHD on the outcome of treatment for depression in

FIG. 1. CDRS-R adjusted total scores for youths with and
without ADHD across the 12-week analysis. Shown is the profile
of treatment-group effects based on the hierarchical linear mixed
regression models completed to compare the outcome of four
treatments during the initial 12 weeks. CDRS-R ¼ Children’s
Depression Rating Scale–Revised; ADHD ¼ attention-deficit=
hyperactivity disorder; COMB ¼ combined treatment of cognitive–behavioral therapy and fluoxetine; FLX ¼ fluoxetine;
CBT ¼ cognitive–behavioral therapy; PBO ¼ pill placebo.

contrasts of mean CDRS-R scores were conducted at week 36 to test
for between-treatment differences within each ADHD subgroup. No
significant difference was found among any of the active treatment
groups in terms of their mean CDRS-R scores.
The ADHD subgroup (n ¼ 43) analysis did not demonstrate any
significant treatment-by-time2 or treatment-by-time interactions.
To examine between-treatment differences in light of the small
sample size per treatment condition, exploratory paired contrasts
were conducted in the absence of a significant treatment-by-time2
interaction within this subgroup. As expected, there were no significant differences in change trajectories or in CDRS-R total
scores at week 36 (all p > 0.050). The separate RRM analysis for
each ADHD subgroup revealed the following, as depicted in Fig. 2.
CGI-I response rate at week 36, using LOCF when a score was
missing, was 75.4% for the youths without ADHD and 62.8% with
ADHD (chi ¼ 3.0, df ¼ 1, p ¼ 0.080).
Psychostimulant treatment of ADHD
At time of randomization to TADS treatment, 20 (32.2%) of the
62 depressed adolescents who were diagnosed with ADHD were
taking a stimulant medication to treat ADHD. Our analysis showed
that CDRS-R depression scores did not prove to be significantly
different for the group of 20 youths treated with a psychostimulant,

FIG. 2. CDRS-R adjusted total scores for youths with and
without ADHD across the 36-week analysis. Shown is the profile
of treatment-group effects based on the random coefficients regression models completed to compare the outcome of three
treatments across 36 weeks. CDRS-R ¼ Children’s Depression
Rating Scale–Revised; ADHD ¼ attention-deficit=hyperactivity
disorder; COMB ¼ combined treatment of cognitive–behavioral
therapy and fluoxetine; FLX ¼ fluoxetine; CBT ¼ cognitive–
behavioral therapy.
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adolescents who participated in TADS. Approximately one in
seven (14.1%) adolescent participants met criteria for a diagnosis
of ADHD. As hypothesized, ADHD was a moderator of treatment
response. We found a differential response to TADS treatment in
the depressed youths with a co-morbid diagnosis of ADHD, as
compared to without ADHD. The ADHD subgroup analyses presented in this paper are exploratory in nature, due to the limited
number of youths in TADS with ADHD, which affects the statistical power to detect significant differences between the subgroups
and increases the possibility of Type II errors (i.e., false negatives).
Although our expectation that depressed adolescent participants
with ADHD would have a less robust response to treatment than
those without ADHD was not met, our prediction of a differential
response moderated by having a diagnosis of ADHD was supported. In TADS youths who had ADHD, the three treatment
groups of COMB, FLX, and CBT had a similarly greater average
rate of improvement during the 12-week blinded treatment compared to PBO. This rate of improvement similarly continued during
the remaining 24 weeks of the study for all three active treatments.
This is a different trajectory, based on rate of improvement, compared to the group of depressed adolescents in TADS who did not
have ADHD.
In our analysis of youths without ADHD, the COMB treatment
group experienced the greatest rate of improvement during the
initial 12 weeks, with COMB superior to PBO. CBT continued to
have a more gradual rate of improvement over the 36-week period
compared to COMB or FLX. By end of treatment at week 36, all
active treatments were similarly effective in alleviating depressive
symptoms in TADS youths, regardless of whether or not they had
ADHD.
Our secondary hypothesis—that participants with ADHD would
prematurely terminate their assigned treatment and drop out of the
study more often than participants without ADHD—was not supported. We found no significant difference between the youths with
or without ADHD in the rate of study dropout or premature termination (i.e., study treatment stopped due to starting a clinicianrecommended nonprotocol treatment). Finally, our hypothesis that
ADHD youths would have higher global impairment and higher
level of suicidality compared to youths without ADHD was also not
supported. Instead we found that as a group ADHD youths did not
differ from those without ADHD in their overall global impairment
or their level of suicidality. In fact, althought we predicted a higher
severity of MDD in the ADHD youths, we found that ADHD youths
in the TADS sample had significantly less severe depressive
symptoms at baseline than those without ADHD, on both the clinician-administered CDRS-R and on the adolescent-completed
RADS. Additionally, there was no difference between those adolescents with and those without ADHD in the age of onset of MDD,
duration of MDD episode, or rate of recurrent depression (all
p > 0.050). There was, however, an increased rate of concurrent
dysthymia in those with ADHD (17.7% vs. 9.3%; p ¼ 0.0448).
We speculate regarding possible reasons for these differing results, particularly that CBT had a superior trajectory of improvement over PBO in youths with ADHD, but not for those without
ADHD. We initially believed that depressed youths with ADHD
would benefit less from CBT due to the cognitive deficits of ADHD
and the cognitive requirements in CBT, such as completing and
applying homework-based concepts. In TADS, parents of ADHD
youths typically described their teens as experiencing significant
levels of inattention, hyperactivity, impulsivity, and emotional lability, in addition to their depression. Despite the elevated levels of
ADHD symptoms, CBT, as offered in TADS, provided an inter-

525

vention that was particularly beneficial for the depressed adolescents with ADHD. It is possible that the CBT in TADS overlaps
with interventions having demonstrated efficacy in the treatment of
ADHD in children (Birmaher et al. 1996; Lewinsohn et al. 1999;
MTA Cooperative Group 1999), such as goal setting, problem
solving, charting of affect regulation, and contingency management. Unfortunately, data on the role of CBT per se in the treatment
of ADHD in children and adolescents are more limited than other
psychosocial interventions, with seminal studies like the MTA
focusing on behavioral interventions rather than CBT.
As the largest study of adolescent depression completed to date,
TADS is one of the few pediatric depression studies with a design
and size adequate to investigate beyond primary comparative outcomes. Unfortunately, our exploratory analysis of the 62 youths in
TADS who had a co-morbid diagnosis of ADHD is still quite
limited in size, which limits the generalizability of our results. If
replicated in future studies, our findings could strengthen guidance
in the treatment of adolescents with co-morbid MDD and ADHD.
In particular, our findings would suggest that any of the three TADS
interventions of CBT, FLX, or COMB may be an appropriate initial
treatment for depression in an adolescent with co-morbid depression and ADHD. The treatment recommendations must be individualized, however, taking into consideration other possible
clinical concerns, co-morbidities, treatment availability, and family
preference,
All three active treatment groups had an average decrease in
mean CDRS-R score of greater than 20 points at week 12, yet
slightly less than half of the co-morbid youths reached much or very
much improvement after 3 months of treatment, suggesting the
need for better treatments for depression, particularly with comorbid ADHD. Further examination of the role of concomitant
ADHD pharmacotherapy during treatment of adolescent depression might prove clinically invaluable, but this is well beyond the
feasibility of our subsample of 20 youths who were treated with a
stimulant medication. We recommend conducting larger studies
that are more adequately powered to examine moderator and mediator analyses, which are needed to better guide clinical treatment
of common co-morbidities in adolescents.
TADS was unique among pediatric MDD trials in allowing
depressed adolescents with co-morbidities such as ADHD to continue taking daily treatment with a psychostimulant. By allowing
such real-world aspects in a controlled study, data such as this
become increasingly relevant to clinical practice. In our analyses,
ADHD moderated the short- and longer-term effects of MDD
treatment in youths with co-morbid ADHD compared to without
ADHD. Our findings indicated that CBT, COMB, and FLX had
similar improvement trajectories in depressed youths with ADHD,
whereas COMB had superior improvement in youths without
ADHD. Thus, our results suggest that any of these three TADS
interventions of CBT, FLX, or COMB may be an appropriate initial
treatment of depression in adolescents with co-morbid ADHD.
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